|ESMO Workshop: Science for Advocates Munich – 13 – 15 October 2017
Click here to apply and for further details. Travel grants available in limited number. ‘Science for advocates’ will be a 2-day interactive workshop (Friday afternoon till Sunday lunch-time) with a combination of lectures, independent and group work. To ensure effective communication, the workshop size will be limited to 35-40 European Cancer patient advocates. Participation is upon application only.
Advocates will have the opportunity to suggest a relevant scientific study of their interest as a test case for the workshop. Otherwise, ESMO faculty will be asked to name one recent relevant study per cancer field.
During the weekend, participants will have the opportunity to directly apply learned content to their study of interest, including the statistical background and the calculation of the ESMO MCBS for that therapy, and generate an infographic representation of the content.
EMBL Workshop Lifelong Learning in Biomedical Sciences Heidelberg- 5 – 7 December 2017
Biomedical research scientists and professionals with successful careers contribute to better research and improved outcomes for patients. Effective continuing professional development can be the catalyst to success for both individual careers and medical advances.
The Lifelong Learning in the Biomedical Sciences Conference 2017 will build on the outcomes and experiences of the 2016 Conference, extending to new topics and a wider audience. The conference will incorporate talks, hands-on workshops, and networking and poster sessions.
This second EMBL conference on Lifelong Learning in the Biomedical Sciences will bring together diverse stakeholders from across the academic, industrial, professional and training sectors to share best practice and actively shape the landscape of continuing professional development in the biomedical sciences. We call upon all who are interested in engaging to shape this future.
EUPATI as an EPF programme is approaching the end of its first year, and EPF President Marco Greco evaluates the achievements – and challenges – of this new environment and shares his perspectives here.
The EUPATI Training Course Patient Experts in Medicines Research & Development has 57 new participants in cohort three. This exciting and unique opportunity offers patient advocates expert-level training in medicines research and development, specifically tailored for them.
Read additional EUPATI news from Germany and Switzerland here.
Hajrah A. Khawaja, a post-graduate student in the School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University of Belfast, UK presents her poster ‘RalB GTPase: A potential novel target for RAS mutant colorectal cancer‘ at the European Society for Medical Oncology conference. ESMO 2017 will be held in Madrid on 8 -12 September 2017. This year’s theme is ‘Integrating science into oncology for a better patient outcome’.
For more information on the conference and programme, please see: http://www.esmo.org/Conferences/ESMO-2017-Congress/Programme
The UNITO team (D. Oddo et al.) has just published Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer in the British Journal of Cancer (DOI: 10.1038/bjc.2017.196).
Background: Combined MET and BRAF inhibition showed clinical benefit in a patient with rectal cancer carrying BRAFV600E and MET amplification. However, after 4 months, acquired resistance emerged and the patient deceased shortly after disease progression. The mechanism of resistance to this drug combination is unknown.
Methods: We analysed plasma circulating tumour DNA obtained at progression by exome sequencing and digital PCR. MET gene and mRNA in situ hybridisation analyses in two bioptic specimens obtained at progression were used to confirm the plasma data.
Results: We identified in plasma MET gene hyper-amplification as a potential mechanism underlying therapy resistance. Increased MET gene copy and transcript levels were detected in liver and lymph node metastatic biopsies. Finally, transduction of MET in BRAF mutant colorectal cancer cells conferred refractoriness to BRAF and MET inhibition.
Conclusions: We identified in a rectal cancer patient MET gene hyper-amplification as mechanism of resistance to dual BRAF and MET inhibition.
MErCuRIC researchers have recently published a review in Nature Reviews Clinical Oncology.
Conor A. Bradley, Manuel Salto-Tellez, Pierre Laurent-Puig, Alberto Bardelli, Christian Rolfo, Josep Tabernero, Hajrah A. Khawaja, Mark Lawler, Patrick G. Johnston, Sandra Van Schaeybroeck & on behalf of the MErCuRIC consortium
Data from many preclinical studies, including those using cellular models of colorectal, gastric, gastro-oesophageal and gastro-oesophageal junction cancers, indicate that the hepatocyte growth factor (HGF)–hepatocyte growth factor receptor (c-MET) pathway is vital for the growth, survival and invasive potential of gastrointestinal cancers. Following the availability of data from these various studies, and data on c-MET expression as a biomarker that indicates a poor prognosis in patients with gastrointestinal cancer and increased c-MET expression, inhibitors targeting this pathway have entered the clinic in the past decade. However, the design of clinical trials that incorporate the use of HGF/c-MET inhibitors in their most appropriate genetic and molecular context remains crucial. Recognizing and responding to this challenge, the European Commission funded Framework 7 MErCuRIC programme is running a biomarker-enriched clinical trial investigating the efficacy of combined c-MET/MEK inhibition in patients with RAS-mutant or RAS-wild-type metastatic colorectal cancer with aberrant c-MET expression. The design of this trial enables the continued refinement of the predictive biomarker and co-development of companion diagnostics. In this Review, we focus on advances in our understanding of inhibition of the HGF/c-MET pathway in patients with gastro-intestinal cancers, the prominent challenges facing the clinical translation and implementation of agents targeting HGF/c-MET, and discuss the various efforts, and associated obstacles to the discovery and validation of biomarkers that will enable patient stratification in this context.
Initiated in 2011 by the EurocanPlatform and since 2016 organized under the umbrella of Cancer Core Europe, the Summer School in Translational Cancer Research will once again take place in Portugal in Albufeira, 16 – 20 October, 2017. The registration deadline is 30 June 2017.
You can learn more about the course here: https://dktk.dkfz.de/en/training/dktk-summer-school/introdution.
Applications are now being accepted for the third EUPATI Expert Training Course.
The EUPATI Training Course Patient Experts in Medicines Research & Development is an exciting and unique opportunity offering patient advocates expert-level training in medicines research and development, specifically tailored for them.
The application deadline is 31 March 2017.
Congratulations to Margaret Grayson, our MErCuRIC Patient Representative, who received a ‘Special Commendation’ for Research Engagement from Cancer Research UK in 2016!
MErCuRIC is funded by the European Community’s Framework Programme Seven (FP7) under contract #602901. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.